These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18564553)

  • 1. The cost of psoriasis.
    Crown WH
    Manag Care; 2003 May; 12(5 Suppl):10-3; discussion 20-1. PubMed ID: 18564553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
    Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
    Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic considerations in psoriasis management.
    Radtke MA; Augustin M
    Clin Dermatol; 2008; 26(5):424-31. PubMed ID: 18755360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States.
    Lin HC; Lucas PT; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2012 Jun; 23(3):196-202. PubMed ID: 21254887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
    Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
    Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of comorbidities in patients with psoriasis is substantial.
    Kimball AB; Guérin A; Tsaneva M; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):157-63. PubMed ID: 20561129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The convergence of psoriasis treatment cost-effectiveness over time: "real world" considerations in economic modeling.
    Goldberg LD
    J Am Acad Dermatol; 2008 Jun; 58(6):1073-5. PubMed ID: 18485990
    [No Abstract]   [Full Text] [Related]  

  • 9. [Psoriasis--clinical picture and current therapy].
    Shakery K; Reich K
    Med Monatsschr Pharm; 2009 Sep; 32(9):335-44; quiz 345-6. PubMed ID: 19795696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
    Al Sawah S; Foster SA; Goldblum OM; Malatestinic WN; Zhu B; Shi N; Song X; Feldman SR
    J Med Econ; 2017 Sep; 20(9):982-990. PubMed ID: 28635342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of psoriasis on health care costs and patient work loss.
    Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
    J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?
    Löfvendahl S; Petersson IF; Theander E; Svensson Å; Zhou C; Steen Carlsson K
    J Rheumatol; 2016 Mar; 43(3):640-7. PubMed ID: 26773111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic criteria for covering medical interventions by the German Public Health Insurance].
    Grell L
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():18-20. PubMed ID: 10941249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-efficacy and pharmacoeconomics of psoriatic patients in Japan: Analysis from a single outpatient clinic.
    Takahashi H; Satoh K; Takagi A; Iizuka H
    J Dermatol; 2019 Jun; 46(6):478-481. PubMed ID: 30942911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home phototherapy for psoriasis is cost-effective.
    Harv Womens Health Watch; 2010 Jul; 17(11):7. PubMed ID: 20687238
    [No Abstract]   [Full Text] [Related]  

  • 18. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review.
    Burgos-Pol R; Martínez-Sesmero JM; Ventura-Cerdá JM; Elías I; Caloto MT; Casado MÁ
    Actas Dermosifiliogr; 2016 Sep; 107(7):577-90. PubMed ID: 27316590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative management of medications for psoriasis and psoriatic arthritis: a review for the dermasurgeon.
    Hernandez C; Emer J; Robinson JK
    Dermatol Surg; 2008 Apr; 34(4):446-59. PubMed ID: 18248470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [With IGeL (Individual Health Allowance) against winter blues].
    Walbert H
    MMW Fortschr Med; 2009 Nov; 151(45):11. PubMed ID: 19960714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.